Halozyme Therapeutics, Inc.

NasdaqGS:HALO 株式レポート

時価総額：US$7.2b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Halozyme Therapeutics マネジメント

マネジメント 基準チェック /24

Halozyme Therapeutics'の CEO はHelen Torleyで、 Jan2014年に任命され、 の在任期間は 10.42年です。 の年間総報酬は$ 11.82Mで、 7.8%給与と92.2%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.53%を直接所有しており、その価値は$ 33.61M 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と10.4年です。

主要情報

Helen Torley

最高経営責任者

US$11.8m

報酬総額

CEO給与比率7.8%
CEO在任期間10.7yrs
CEOの所有権0.5%
経営陣の平均在職期間2.6yrs
取締役会の平均在任期間10.7yrs

経営陣の近況

Recent updates

Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals

Aug 14

Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Aug 13
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar

Jul 17
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar

Halozyme Therapeutics: The Story Brightens

Jun 07

Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Apr 26
Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics

Apr 10

Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Apr 05
Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Mar 15
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 23
Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Jan 26

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Jan 10
These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Dec 14
Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Sep 22
Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jul 04
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

May 09
We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Mar 28
Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Jan 23
Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Dec 09
Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CEO報酬分析

Halozyme Therapeutics の収益と比較して、Helen Torley の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

US$337m

Mar 31 2024n/an/a

US$319m

Dec 31 2023US$12mUS$920k

US$282m

Sep 30 2023n/an/a

US$254m

Jun 30 2023n/an/a

US$234m

Mar 31 2023n/an/a

US$182m

Dec 31 2022US$10mUS$872k

US$202m

Sep 30 2022n/an/a

US$211m

Jun 30 2022n/an/a

US$366m

Mar 31 2022n/an/a

US$435m

Dec 31 2021US$7mUS$830k

US$403m

Sep 30 2021n/an/a

US$409m

Jun 30 2021n/an/a

US$229m

Mar 31 2021n/an/a

US$163m

Dec 31 2020US$7mUS$791k

US$129m

Sep 30 2020n/an/a

US$22m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$80m

Dec 31 2019US$6mUS$761k

-US$72m

Sep 30 2019n/an/a

-US$40m

Jun 30 2019n/an/a

-US$43m

Mar 31 2019n/an/a

-US$51m

Dec 31 2018US$6mUS$725k

-US$80m

Sep 30 2018n/an/a

US$46m

Jun 30 2018n/an/a

US$76m

Mar 31 2018n/an/a

US$68m

Dec 31 2017US$5mUS$671k

US$63m

報酬と市場: Helenの 総報酬 ($USD 11.82M ) は、 US市場 ($USD 8.45M ) の同規模の企業の平均を上回っています。

報酬と収益: Helenの報酬は過去 1 年間で 20% 以上増加しました。

CEO（最高経営責任者

Helen Torley (61 yo)

10.7yrs

在職期間

US$11,820,858

報酬

Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. He serves as President, CEO & Director at Halozyme, Inc. Prio...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Helen Torley
President10.7yrsUS$11.82m0.53%
$ 38.6m
Nicole LaBrosse
Senior VP & CFO2.6yrsUS$3.85m0.012%
$ 881.9k
Michael LaBarre
Senior VP & CTOno dataUS$3.24m0.14%
$ 9.9m
Mark Snyder
Senior VP & Chief Legal Officer2.7yrsUS$3.61m0.0092%
$ 665.4k
Cortney Caudill
Chief Operations Officerless than a yearデータなしデータなし
Tram Bui
Head of Investor Relations & Corporate Communications2.7yrsデータなしデータなし
Amy Fox
Chief Human Resources Officer4.7yrsデータなしデータなし
Gary Grote
Chief Commercial Officer1.3yrsデータなしデータなし
Christopher Wahl
Chief Business Officer1.2yrsデータなしデータなし

2.6yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: HALOの経営陣は 経験豊富 であると考えられます ( 2.4年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Helen Torley
President10.7yrsUS$11.82m0.53%
$ 38.6m
Connie Matsui
Independent Director18.2yrsUS$460.02k0.15%
$ 10.7m
Jeffrey Henderson
Independent Chair of the Board9.1yrsUS$555.02k0.037%
$ 2.7m
Daniel Von Hoff
Member of the Scientific Advisory Board20.1yrsデータなしデータなし
Barbara Duncan
Independent Director1.6yrsUS$528.15kデータなし
Jeffrey Bleil
Member of the Advisory Boardno dataデータなしデータなし
Gregory Frost
Chairman of Scientific Advisory Board10.7yrsUS$68.17kデータなし
Gerhard Baumgartner
Member of Scientific Advisory Board20.3yrsデータなしデータなし
Sue Bailey
Member of Scientific Advisory Board19.2yrsデータなしデータなし
Matthew Posard
Independent Director11.5yrsUS$471.83k0.039%
$ 2.8m
Akiko Miyashita
Independent Director2.5yrsUS$455.02k0.011%
$ 813.3k
Bernadette Connaughton
Independent Director6yrsUS$470.02k0.032%
$ 2.3m

10.7yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: HALOの 取締役会 は経験豊富で 経験豊富 です ( 10.4年の平均在任期間)。